Evaluation of the burden of illness in patients with mild to moderate Crohn disease

Drug Benefit Trends

Volumn 16, Issue 12, 2004, Pages 600-609

  Joshua Gotlib, Sandra ^a   Coyne, Karin ^b   Kimel, Miriam ^b   Danilewitz, Mervyn ^a   Thompson, Christine ^b   Forget, Sylviane ^c  

^a ASTRAZENECA   (United Kingdom)

^b Center for Health Outcomes Research   (United States)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Crohn disease; Health related quality of life; Treatment satisfaction; Work productivity

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; CYTOKINE RECEPTOR AGONIST; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; OLSALAZINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANALYSIS OF VARIANCE; ARTICLE; BODY BURDEN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORBIDITY; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PHYSICAL DISEASE; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; STUDENT T TEST; SYMPTOM; TREATMENT OUTCOME; WORK;

EID: 15444369327     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
2. Hanauer SB, Sandborn W; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
3. Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51-60.
4. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-amino-salicylate therapy. Eur J Gastroenterol Hepatol. 2001;13:1297-1301.
5. Rutgeerts PJ. Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm Bowel Dis. 2001;7(suppl 1):S2-S8.
6. Sandborn WJ, Feagan BG. Mild to moderate Crohn's disease - defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003;18:263-277.
7. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6:522-531.
8. Decision Resources. Crohn's disease market assumptions, 2000-2010. In: DecisionBase 6: Crohn's Disease. Waltham, Mass: Decision Resources, Inc; 2002:43.
9. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology. 1979;77(4 pt 2):829-842.
10. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96: 804-810.
11. Irvine EJ, Feagan B, Rochon J, et al; Canadian Crohn's Relapse Prevention Trial Study Group. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology. 1994;106:287-296.
12. Irvine EJ. Effects of budesonide therapy on quality of life in active Crohn's disease. Res Clin Forums. 1996;18:81-89.
13. Coyne KS, Wiklund I, Schmier J, et al. Development and validation of a disease-specific treatment satisfaction questionnaire for gastrooesophageal reflux disease. Aliment Pharmacol Ther. 2003;18:907-915.
14. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
15. Reilly MC. Work Productivity and Activity Impairment Questionnaire (WPAI) User's Manual. New York: Reilly Associates; 2001.
16. Sutherland LR, Martin F, Bailey RJ, et al, for the Canadian Mesalamine for Remission of Crohn's Disease Study Group. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. Gastroenterology. 1997;112:1069-1077.
17. Bresci G, Parisi G, Bertoni M, et al. Does the initial location of Crohn's disease have an influence on the time-to-relapse in patients under maintenance treatment with oral mesalamine? J Clin Gastroenterol. 2000;31:147-151.
18. Wahlqvist P. Measuring indirect costs: relevant to decision-makers. Presented at: International Society for Pharmacoeconomics and Outcomes Research 5th Annual European Congress, Contributed Issue Panel; November 3-5, 2002; Rotterdam, the Netherlands.
19. Ward FM, Bodger K, Daly MJ, Heatley RV. Clinical economics review: medical management of inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:15-25.